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Purpose: To describe the clinical and genetic findings in one Chinese family with juvenile-onset open angle glaucoma
(JOAG).
Methods: One family was examined clinically and a follow-up took place 5 years later. After informed consent was
obtained, genomic DNA was extracted from the venous blood of all participants. Linkage analysis was performed with
three microsatellite markers around the MYOC gene (D1S196, D1S2815, and D1S218) in the family. Mutation screening
of all coding exons of MYOC was performed by direct sequencing of PCR-amplified DNA fragments and restriction
fragment length polymorphism (RFLP) analysis. Bioinformatics analysis by the Garnier-Osguthorpe-Robson (GOR)
method predicted the effects of variants detected on secondary structures of the MYOC protein.
Results: Clinical examination and pedigree analysis revealed a three- generation family with seven members diagnosed
with JOAG, three with ocular hypertension, and five normal individuals. Through genotyping, the pedigree showed a
linkage to the MYOC on chromosome 1q24–25. Mutation screening of MYOC in this family revealed an A→T transition
at position 1348 (p. N450Y) of the cDNA sequence. This missense mutation co-segregated with the disease phenotype of
the family, but was not found in 100 normal controls. Secondary structure prediction of the p.N450Y by the GOR method
revealed the replacement of a coil with a β sheet at the amino acid 447.
Conclusions: Early onset JOAG, with incomplete penetrance, is consistent with a novel mutation in MYOC. The finding
provides pre-symptomatic molecular diagnosis for the members of this family and is useful for further genetic consultation.
Primary open-angle glaucoma (POAG;OMIM 137760)
is one of the leading causes of blindness in the world [1]. It is
a  neurodegenerative  disorder  characterized  by  progressive
excavation of the optic discs due to loss of retinal ganglion
cells. It is usually associated with elevation of intraocular
pressure (IOP) [2]. Based upon the age of diagnosis, primary
open-angle glaucoma can be sub-classified to either juvenile-
onset primary open-angle glaucoma (JOAG) or adult-onset
primary open-angle glaucoma. JOAG is a relatively rare form
of primary open angle glaucoma that occurs in children and
young  adults.  The  exact  age  boundary  for  juvenile-onset
varies from one study to the next, but it usually falls between
35 and 40 years of age [2].
Strong evidence indicates that genetic factors play a role
in the pathogenesis of glaucoma. About 30%–56% of patients
with glaucoma or ocular hypertension (OHT) have a positive
family history; first-degree relatives of POAG patients are
seven to ten times more likely to have POAG, compared with
the general population [3,4]. Genetically, most POAG cases
follow  a  complex  (non-Mendelian)  pattern  of  inheritance,
which  manifests  clinically  in  adulthood  (>40  years).
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However,  juvenile-onset  open-angle  glaucoma  typically
shows an autosomal dominant inheritance [2-4]. To date, three
genes, namely myocilin (MYOC), optineurin (OPTN), and
WD  repeat-containing  protein  36  (WDR36),  have  been
reportedly linked to POAG [5-10]. MYOC (OMIM 601652)
was the first gene to be identified as responsible for POAG.
Mutations in MYOC account for over 8% of JOAG and 3%–
4% of adult-onset POAG [11,12].
MYOC, consisting of three exons, encodes 504 amino
acid residues. Myocilin is an acidic protein that contains an
NH2-terminal  myosin-like  domain  and  a  COOH-terminal
olfactomedin-like domain [6]. Almost 80 mutations have been
found in MYOC and about 90% of the mutations are located
in  the  olfactomedin-like  domain  encoded  by  exon3  [6,
11-30].
In  this  study,  we  describe  the  clinical  findings  in  a
Chinese family with a novel MYOC mutation.
METHODS
Patients  and  DNA  sample  collection:  This  study  was
performed  according  to  the  tenets  of  the  Declaration  of
Helsinki for research involving human subjects. This study
was  approved  by  the  Beijing  Tongren  Hospital  Joint
Committee on Clinical Investigation. After informed consent
was  obtained,  all  participants  underwent  ophthalmologic
examination including bilateral best corrected visual acuity
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1728using E decimal charts, slit-lamp biomicroscopy inspection of
the anterior chamber, intraocular pressure (IOP) measurement
by  applanation  tonometry  (Goldmann),  anterior  chamber
angle  evaluation  by  gonioscopy  (Goldmann),  and  fundus
examination with a 66-diopter VOLK lens. Most members
were clinically followed for five years, from 2004 to 2009.
Some  individuals  underwent  Octopus’s  perimeter
examination.  Diagnosis  of  POAG  was  based  on  the
observation of at least two of the following abnormalities:
characteristic glaucomatous optic disc changes, characteristic
glaucomatous  visual  field  defects,  and  high  intraocular
pressure  (>21  mmHg)  in  the  presence  of  a  normal  open
anterior chamber angle. Characteristic glaucomatous optic
disc changes include vertical cup-disc (c/d) ratio of 0.7 or
more,  notching  of  the  neutral  rim,  and  disc  hemorrhage.
Subjects were sub-classified JOAG if the diagnosis of POAG
was made before 35 years of age. Individuals with intraocular
pressure greater than 22 mmHg but with no characteristic
optic disc damage or visual field impairment were defined as
ocular hypertension. Unaffected people had IOP in the normal
range (≤21 mmHg) and optic nerves presented normal in
appearance.
Linkage  analysis:  Genotyping  and  linkage  analysis  were
performed  with  three  microsatellite  markers  (D1S196,
D1S2185, and D1S218) around the MYOC gene in the family.
The fine mapping primer sequences were obtained from the
GDB Human Genome Database. LOD scores were calculated
for  the  two  markers  by  two-point  linkage  analysis  using
linkage package 5.2. We modeled the disease as an autosomal
dominant  trait  with  reduced  penetrance.  Pedigree  and
haplotype maps were constructed using Cyrillic version 2.0
software.
Mutation screening of MYOC: Peripheral blood was obtained
by venipuncture and genomic DNA was extracted according
to standard protocols. The entire coding region of MYOC was
amplified by polymerase chain reaction (PCR) from genomic
DNA. Primers for three exons and exon-intron boundaries of
MYOC were designed by the Primer3 program. These primer
sequences are presented in Table 1. For direct sequencing,
PCR  products  were  purified  (Shenneng  Bocai  PCR
TABLE 1. PCR PRIMERS USED IN THIS STUDY.
Primer Forward (5'-3') Reverse (5'-3') Tm (°C) Product size (bp)
exon1 CTCTGTCTTCCCCCATGAAG AGCAGGTCACTACGAGCCATA 62 785
exon2 TAGTCAATCCTTGGGCCATT ACCACGTGGGCACAAAAG 60 561
exon3-1 CTTCCGCATGATCATTGT CTTCCGCATGATCATTGT 58 352
exon3-2 ATACTGCCTAGGCCACTGGAA CCGCTATAAGTACAGCAGCATGAT 58 440
exon3-3 GCCTTCATCATCTGTGGCAC CAGGCAGCTTTGACTGCTTT 58 342
Figure  1.  Family  structure  and
haplotype analysis of a Chinese family
with  JOAG.  Pedigree  and  haplotype
analysis  of  the  family  with  JOAG
showed  segregation  with  three
microsatellite markers on chromosome
1, listed in descending order from the
centromeric  end.  Squares  indicate
males; circles indicate females; slashed
symbols  indicate  deceased;  solid
symbols  indicate  affected;  open
symbols  indicate  unaffected;  symbols
with  upper  left  filled-in  quadrant
indicate  members  with  ocular
hypertension; symbols with dot in the
center indicate carriers.
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1729purification kit; Shenneng, Shanghai, China). An automatic
fluorescence  DNA  sequencer  (ABI,  Prism  373A;  Perkin
Elmer, Foster City, CA), used according to the manufacturer’s
instructions, was used to sequence the purified PCR products
in both forward and reverse directions. DNAssist Version 1.0
compared  nucleotide  sequences  with  the  published  DNA
sequence of MYOC (GenBank NM_000261). For the MYOC
gene, cDNA numbering +1 corresponded to the A in the ATG
translation initiation codon of MYOC.
Restriction fragment length polymorphism (RFLP) analysis:
To confirm the variations found in the sequencing, restriction
endonuclease HindII (New England Biolabs, Ipswich MA)
was used in all available family members and in 100 normal
control  subjects.  The  reaction  was  performed  in  a  10  μl
volume containing 9.4 μl PCR product, 0.1 μl BSA (100 μg/
ml), and 0.5 μl enzyme (10 U/μl). After incubating the reaction
overnight at 37 °C, the entire digest was run on a 1% agarose
gel and visualized under ultraviolet light.
Bioinformatics  analysis:  Garnier-Osguthorpe-Robson
(GOR) software was used to predict the effect of the mutation
on the secondary structure of MYOC [31]. This method infers
the  secondary  structure  of  a  sequence  by  calculating  the
probability for each of the four structure classes (helix, sheet,
turn, and loop) based on the central residue and its neighbors
from the calculated matrices.
RESULTS
Clinical  findings:  We  have  identified  a  three-  generation
family diagnosed with JOAG. The inheritance pattern in this
family appeared to be autosomal dominant (Figure 1). After
clinical  examinations  and  hospital  records  reviewing,  six
individuals of this pedigree were found to have glaucoma in
2004. The patient in the first generation had not received any
treatment and totally lost her sight before the age of 35. The
remaining five patients underwent trabeculectomies in both
eyes. The mean onset age of these patients was 27.42 years
(ranging from 20 to 31 years old), which was consistent with
juvenile  glaucoma.  All  patients  experienced  elevated  IOP
(32–50 mmHg) and most of them presented typical late stage
glaucoma changes in the optic disc and in the visual field
(Figure 2A). In 2004, six members were diagnosed with ocular
hypertension (IOPs were higher than 22 mmHg) but without
optic disc or visual field changes. A five-year follow-up was
conducted with fifteen of the seventeen individuals and their
blood samples were collected for further genetic analysis. At
the 5-year follow-up, two ocular hypertension patients (Figure
1; III:2 and III:7) were newly diagnosed with glaucoma due
to their elevated IOP, enlarged cup/disc ratio of the optic disc,
and early visual field changes in 2009 (Figure 2B) . Detailed
clinical information of the pedigree is summarized in Table 2.
Genotyping results: The family was genotyped with three
STRP  markers  located  around  the  MYOC  gene  in  the
chromosome 1q24–25 region. The marker results for D1S218
and D1S2815 were fully informative for linkage. There was
no affected (glaucomatous patients and ocular hypertension
patients) recombinant for either of the two makers (Figure 1).
Two  clinical  unaffected  individuals  (II:12  and  III:12),
however, were found to be carrying the affected haplotype.
Figure  2.  Fundus  appearances  of
patients with JOAG. A: Fundus images
of II:7 showed late-stage glaucomatous
cupping  of  the  optic  disc.  B:  Fundus
images of III:7, who was confirmed to
have glaucoma in 2009, presented early
glaucomatous appearances of the optic
disc.
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1731Therefore, the disease penetrance appeared incomplete in this
pedigree. Two-point LOD scores for D1S2815 and D1S218
with  80%  penetrance  were  2.40  (θ=0.0)  and1.63  (θ=0.0),
respectively.
Mutation analysis: By direct sequencing of three exons of
MYOC, we found a novel base change (A→T) at position 1348
of MYOC cDNA, replacing asparagine with tyrosine at amino
acid 450 residue (Figure 3A). This heterozygous missense
mutation abolished a HindII restriction site that segregated
with all affected members and ocular hypertension individuals
in  this  Chinese  family,  but  that  was  not  detected  in  100
unrelated normal controls. As observed in the genotyping, two
clinical unaffected individuals (II:12 and III:12) carried the
mutation as well (Figure 3B).
Prediction  of  two-dimensional  structure:  Using  the  GOR
method,  the  results  for  secondary  structure  prediction
suggested that the mutant MYOC450Y replace a coil “C” with
a β sheet “E” at amino acid 447 Figure 4).
DISCUSSION
This  study  described  a  Chinese  family  with  clinically
diagnosed juvenile-onset open angle glaucoma. By screening
the MYOC gene, we identified a novel heterozygous missense
mutation p. N450Y in the pedigree. The mutation p. N450Y
co-segregated  with  all  glaucoma  patients  and  ocular
Figure  3.  DNA  sequence
chromatograms  and  co-segregation
analysis of the p.N450Y mutation with
disease  phenotype.  A:  Heterozygote
sequence (sense strand) shows an A/T
transition  in  codon  450  that  changed
asparagine  (AAC)  to  tyrosine  (TAC).
B: Restriction fragment length analysis
shows the p.N450Y mutation abolishing
a HindII site co-segregated with JOAG
patients, ocular hypertensions, and the
carriers (342 and 279 bp), but not with
unaffected individuals (279 bp).
Figure 4. The effect of p. N450Y on the
secondary structure of MYOC using the
GOR  method.  A:  The  secondary
structure of wild type MYOC around the
site N450. B: The secondary structure of
mutant  Y450  of  MYOC  of  the
corresponding region.
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1732hypertension individuals, but was not detected in 100 normal
controls.
MYOC was the first disease-causing gene identified for
POAG  and  almost  80  mutations  have  been  reported  [6,
11-30]. Mutations in MYOC are racial/ethnic specific and
some of them have been found only in a specific region [6,
11-30]. So far, 11 MYOC mutations have been identified in
Chinese patients or pedigrees and seven of them were Chinese
specific (Table 3) [19,20,22,23,25,26,28].
The  Asn450  residue,  located  in  the  olfactomedin-like
domain, is highly conserved in humans, rats, mice, cattle,
dogs, and zabrafish (Figure 5). The results of GOR suggested
that  p.N450Y  lead  to  a  secondary  structure  change  by
replacing a coil structure with a β sheet around the Asn450
residue, which might interfere with the correct folding of the
protein. In a large case control study, another mutation (p.
N450D) was also detected at the Asn450 residue in a sporadic
Germany patient [18]. This may imply that the Asn450 residue
is very important for the activity of the olfactomedin-like
domain.
Phenotype  and  genotype  correlation  has  been  well
established in some MYOC mutations [11,12,27]. Patients
carrying the P370L mutation usually developed glaucoma at
a very early age, with high levels of IOP, which responds
poorly to medical treatment [12,32,33]; while patients with
the Q368X mutation were diagnosed with glaucoma at a later
adult age and their maximum IOPs were around 30 mmHg,
which could be well controlled by medical therapy [12,34,
35].  One  American  family  carrying  the  p.D380H  MYOC
mutation presented with an intermediate phenotype between
juvenile and adult onset glaucoma [36]. In the current study,
the onset age of glaucoma ranged from 20 to 31 years (mean
26 years). The mean highest IOP was 48.57 mmHg (range
from 32 to 60 mmHg). One patient totally lost her sight before
35 years of age. Except for two patients newly diagnosed in
2009, the remaining five patients responded poorly to medical
therapy  and  required  filtration  surgery  for  long-term  IOP
control. Five individuals diagnosed with ocular hypertension
in 2004 carried the mutation p.N450Y and their mean age at
diagnosis was 17.8 years. At the 5-year follow up, two of them
presented glaucomatous optic disc change and were newly
diagnosed  with  glaucoma.  The  phenotype  and  genotype
correlation study on seven patients in this pedigree indicated
that  affected  members  carrying  the  mutation  p.N450Y
experienced more severe symptoms at an earlier age.
Incomplete  penetrance  has  been  observed  in  most
families with MYOC mutations and the penetrances are age-
dependent and mutation-specific [11,12,27]. The penetrance
of pedigrees carrying p. P370L was 100% at age 30 years
[12,32,33], while it was 0 for the pedigrees with Q368X [12,
34,35]. In this pedigree, two clinically healthy individuals and
three ocular hypertension patients were found harboring both
mutation p.N450Y and the affected haplotype. The penetrance
of this pedigree was 50% (6/12) at age 30 and almost 60%
(7/12)  at  age  35  years.  More  than  80%  (10/12)  of  the
individuals carrying the p.N450Y mutation have developed
glaucoma  or  ocular  hypertension.  Interestedly,  one  of  the
healthy members (II-12) was already 39 years old, which was
TABLE 3. MUTATIONS IN MYOC IDENTIFIED IN CHINESE FAMILIES OR PATIENTS.
Mutation Location Case
control
Family-base Phenotype Proband age
at diagnosis
Country/ethnicity Reference
R91X Exon1 Yes   NA   China [19]
C245Y Exon3 Yes Yes JOAG 16 China [22,23]
G252R Exon3 Yes Yes JOAG 29 Caucasian, China [12,20]
E300K Exon3 Yes   NA NA China [19,22]
S313F Exon3 Yes   NA NA China [22]
Q337X Exon3   Yes JOAG 40** China [28]
S341P Exon3   Yes JOAG 24 China, Korean [14,26]
T353I* Exon3 Yes   NA NA Asian [19,22]
P370L Exon3 Yes Yes JOAG 11 Caucasian, Asian [12,27,32,33]
N450Y Exon3   Yes JOAG 20 China Present study
T455K Exon3   Yes JOAG 26 China [25]
Y471C Exon3 Yes   NA NA China [19,22]
        The asterisk indicates uncertain pathogenicity and the double asterisk indicates the proband was in the end stage of glaucoma.
         NA refers date is unavailable.
Figure 5. Sequence alignment portion of
the olfactomedin-like domain spanning
the novel missense mutation p.N450Y
of human MYOC and a comparison with
other species.
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1733ten years older than the average onset age of this family; this
implied  that  other  unidentified  factors  (genetic  or
environmental) might be associated with the JOAG of this
pedigree.  However,  whole  carriers  should  undergo
ophthalmologic surveillance at regular intervals for the rest of
their lives.
In  summary,  the  report  described  a  novel  conserved
tyrosine  to  asparagine  substitution  at  exon  3  of  MYOC
associated with an early-onset and severe juvenile-onset open
angle glaucoma pedigree. The results further expanded the
mutation spectrum of MYOC and characterized the genotype-
phenotype correlations of this pedigree. These results provide
pre-symptomatic molecular diagnosis for the members of the
pedigree and are useful for further genetic consultation with
this family.
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